122 related articles for article (PubMed ID: 26115900)
1. The Impact of Metabolic Syndrome on Clinical Outcomes After Everolimus-Eluting Stent Implantation.
Lee Y; Lim YH; Shin JH; Park J; Shin J; Kim KS
Am J Cardiol; 2015 Sep; 116(5):717-24. PubMed ID: 26115900
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.
Ji MS; Jeong MH; Ahn YK; Kim SH; Kim YJ; Chae SC; Hong TJ; Seong IW; Chae JK; Kim CJ; Cho MC; Rha SW; Bae JH; Seung KB; Park SJ; Hur SH;
Int J Cardiol; 2015 Nov; 199():53-62. PubMed ID: 26186631
[TBL] [Abstract][Full Text] [Related]
3. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation.
Choi IJ; Koh YS; Lim S; Kim JJ; Chang M; Kang M; Hwang BH; Kim CJ; Kim TH; Seo SM; Shin DI; Park MW; Choi YS; Park HJ; Her SH; Kim DB; Kim PJ; Lee JM; Park CS; Moon KW; Chang K; Kim HY; Yoo KD; Jeon DS; Chung WS; Seung KB
Am J Cardiol; 2014 Feb; 113(3):457-64. PubMed ID: 24332246
[TBL] [Abstract][Full Text] [Related]
4. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
[TBL] [Abstract][Full Text] [Related]
5. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
7. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes after percutaneous coronary intervention for chronic total occlusion using everolimus- versus sirolimus- versus paclitaxel-eluting stents (from the Korean National Registry of Chronic Total Occlusion Intervention).
Lee MH; Lee JM; Kang SH; Yoon CH; Jang Y; Yu CW; Park HS; Lee SH; Hur SH; Kim MH; Rha SW; Gwon HC; Chae IH; Kim HS
Am J Cardiol; 2015 Jul; 116(2):195-203. PubMed ID: 26001819
[TBL] [Abstract][Full Text] [Related]
9. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
[TBL] [Abstract][Full Text] [Related]
10. Impact of gender on clinical outcomes after mTOR-inhibitor drug-eluting stent implantation in patients with first manifestation of ischaemic heart disease.
Niccoli G; Sgueglia GA; Cosentino N; Piro M; Toma A; Cataneo L; Fracassi F; Porto I; Leone AM; Burzotta F; Trani C; Crea F
Eur J Prev Cardiol; 2012 Oct; 19(5):914-26. PubMed ID: 21840968
[TBL] [Abstract][Full Text] [Related]
11. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
12. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
14. Intravascular Ultrasound Predictors of Major Adverse Cardiovascular Events After Implantation of Everolimus-eluting Stents for Long Coronary Lesions.
Lee SY; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):88-95. PubMed ID: 27789170
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
[TBL] [Abstract][Full Text] [Related]
17. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the randomized comparison of everolimus-eluting stents and sirolimus-eluting stent in patients with ST elevation myocardial infarction (RACES-MI trial).
Di Lorenzo E; Sauro R; Capasso M; Lanni F; Lanzillo T; Carbone G; Manganelli F; Palmieri V; Serino V; Pagliuca MR; Rosato G; Suryapranata H; De Luca G
Int J Cardiol; 2016 Jan; 202():177-82. PubMed ID: 26397405
[TBL] [Abstract][Full Text] [Related]
19. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
[TBL] [Abstract][Full Text] [Related]
20. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease.
Machado C; Raposo L; Dores H; Leal S; Campante Teles R; de Araújo Gonçalves P; Mesquita Gabriel H; Almeida M; Mendes M
Coron Artery Dis; 2014 May; 25(3):208-14. PubMed ID: 24419038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
